SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Exelixis, Inc. EXEL today announced the presentation of
additional data from clinical trials of COMETRIQ™ (cabozantinib) in
patients with progressive, metastatic medullary thyroid cancer (MTC).
The data were presented this weekend at the 2013 Annual Meeting of the
American Society of Clinical Oncology (ASCO). Long-term follow-up of a
phase 1 trial (Abstract #6090) shows that 30% of progressive, metastatic
MTC patients treated with COMETRIQ experienced disease control (DC) and
have remained progression-free for more than 2 years. A separate
presentation (Abstract #6000) reports data from the prospective analysis
of RET mutational status and retrospective ad hoc analysis of RAS
mutational status of patients in EXAM, Exelixis' phase 3 pivotal trial
of COMETRIQ in progressive, metastatic MTC. These data show
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in